Up until recently, the stock has been a chronic underperformer.

Pfizer reported positive Phase 3 results for TALZENNA (talazoparib) in combination with XTANDI in HRR gene mutated metastatic ...

If you are wondering whether Pfizer's current share price reflects its long term potential or lingering concerns, looking ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer expands oncology and immunology pipeline strength New therapies show progress in clinical development Focus shifts ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...